These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33251600)

  • 41. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
    Werfel T
    J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis.
    Fröschl B; Arts D; Leopold C
    GMS Health Technol Assess; 2007 Sep; 3():Doc09. PubMed ID: 21289943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis.
    Siegfried E; Korman N; Molina C; Kianifard F; Abrams K
    J Dermatolog Treat; 2006; 17(3):143-50. PubMed ID: 16854753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.
    Prucha H; Schnopp C; Akdis C; Lauener R; Wollenberg A; Ring J; Traidl-Hoffmann C
    Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1507-16. PubMed ID: 23876065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
    Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
    Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis.
    Pena J; Zameza PA; Pixley JN; Remitz A; Feldman SR
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1347-1359. PubMed ID: 36997119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.
    Reitamo S; Remitz A; Kyllönen H; Saarikko J
    Am J Clin Dermatol; 2002; 3(6):381-8. PubMed ID: 12113647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.
    Pitt M; Garside R; Stein K
    Br J Dermatol; 2006 Jun; 154(6):1137-46. PubMed ID: 16704646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis.
    Sun SL; Liu JJ; Zhong B; Wang JK; Jin X; Xu H; Yin FY; Liu TN; Chen QM; Zeng X
    Br J Dermatol; 2019 Dec; 181(6):1166-1176. PubMed ID: 30903622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Safety of topical tacrolimus and pimecrolimus in children with atopic dermatitis].
    Rodríguez Orozco AR; Ruiz Reyes H; Marín Hernández D
    Rev Alerg Mex; 2005; 52(4):171-6. PubMed ID: 16268186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
    Lübbe J; Friedlander SF; Cribier B; Morren MA; García-Díez A; Gelmetti C; Hofmann H; Houwing RH; Kownacki S; Langley RG; Virtanen M; Wolff K; Wisseh S; McGeown C; Abrams B; Schneider D;
    Am J Clin Dermatol; 2006; 7(2):121-31. PubMed ID: 16605292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
    Chen SL; Yan J; Wang FS
    J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Contemporary Role of Topical Calcineurin Inhibitors: A Pediatric Dermatology Perspective.
    Fiorillo L; Marcoux D; Ramien M
    J Cutan Med Surg; 2019; 23(4_suppl):11S-18S. PubMed ID: 31476940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Munzenberger PJ; Montejo JM
    Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.
    Garside R; Stein K; Castelnuovo E; Pitt M; Ashcroft D; Dimmock P; Payne L
    Health Technol Assess; 2005 Jul; 9(29):iii, xi-xiii,1-230. PubMed ID: 16022804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
    Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
    Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Hultsch T; Kapp A; Spergel J
    Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
    Wolff K
    Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    de Bruin-Weller MS; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.